Related Experiment Video
Updated: Nov 14, 2025

Generation of Genomic Deletions in Mammalian Cell Lines via CRISPR/Cas9
Published on: January 3, 2015
Erasing iatrogenic neoantigens from in vivo CRISPR screens
Fei Yi1, Christopher A Klebanoff2
1Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Center for Cell Engineering, MSKCC, New York, NY 10065, USA.
Abstract:
In vivo genetic screens using CRISPR-Cas9 are a powerful tool to resolve the molecular determinants of response and resistance to cancer immunotherapies; however, vector immunogenicity can introduce artifact. In this issue of Immunity, Dubrot et al. report a strategy to "erase" vector-associated neoantigens, enabling a more physiologic assessment of tumor-immune cell interactions in immunocompetent hosts.
Related Concept Videos
CRISPR
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
CRISPR/Cas9 Genome Editing
In-vitro Mutagenesis

